MHRA: Plozasiran Redemplo Authorization for FCS Treatment

• The MHRA authorized plozasiran (Redemplo) on October 19, 2026, for adults with familial chylomicronaemia syndrome (FCS).
• Plozasiran reduces triglyceride levels by blocking apolipoprotein C3 production and is administered as a quarterly subcutaneous injection.
• A clinical study showed an 80% median triglyceride reduction in plozasiran recipients compared to 17% in the placebo group over 10 months.
• Common side effects include hyperglycemia, headache, nausea, and injection site reactions, with ongoing safety monitoring via the Yellow Card scheme.
• The authorization was granted to Arrowhead Pharmaceuticals Ireland Limited via the International Recognition Procedure (IRP), Route B, using the EMA as the reference regulator.

This crucial MHRA plozasiran Redemplo authorization, issued on October 19, 2026, marks a pivotal development for individuals grappling with this rare genetic disorder, which is characterized by dangerously elevated levels of fats in the blood.

The Medicines and Healthcare products Regulatory Agency (MHRA) has officially granted authorization for plozasiran (Redemplo), a novel treatment designed to significantly lower triglyceride levels in adult patients diagnosed with familial chylomicronaemia syndrome (FCS). This crucial MHRA plozasiran Redemplo authorization, issued on October 19, 2026, marks a pivotal development for individuals grappling with this rare genetic disorder, which is characterized by dangerously elevated levels of fats in the blood. The approval specifies that the medication must be used in conjunction with a carefully managed low-fat diet.

Familial chylomicronaemia syndrome presents a serious health challenge, as the accumulation of high triglycerides can precipitate severe abdominal pain and inflammation of the pancreas, a condition known as pancreatitis. Plozasiran functions by inhibiting the synthesis of apolipoprotein C3, a protein produced in the liver that typically impedes the breakdown of fats. By reducing the presence of this protein, the new drug approval UK facilitates a more efficient reduction of triglyceride concentrations in the bloodstream. The treatment is administered as a 25 mg injection beneath the skin once every three months, with provisions for patients or their caregivers to perform the injection following appropriate training.

The decision to authorize plozasiran (Redemplo) was underpinned by robust clinical trial data, which demonstrated its substantial efficacy in managing FCS. A primary study involving 75 adult participants with familial chylomicronaemia syndrome, all adhering to a controlled dietary regimen, provided compelling evidence. In this trial, 50 individuals received plozasiran, while the remaining 25 were given a placebo. Over a 10-month period, those treated with plozasiran experienced a median reduction in triglyceride levels of approximately 80%, a stark contrast to the 17% reduction observed in the placebo group.

Beyond its impact on triglyceride levels, the study also indicated a decrease in the incidence of acute pancreatitis episodes among patients receiving plozasiran. While generally well-tolerated, the treatment does carry a safety profile that includes potential side effects. Hyperglycaemia, or elevated blood sugar, was reported in more than one in ten individuals. Other common adverse reactions, affecting up to one in ten people, encompassed headaches, nausea, and localized reactions at the injection site. The MHRA emphasizes the importance of reporting any suspected side effects through the established Yellow Card scheme, accessible via its website or dedicated app, to ensure ongoing safety monitoring.

This significant Redemplo UK approval was granted to Arrowhead Pharmaceuticals Ireland Limited through the International Recognition Procedure (IRP), specifically Route B, leveraging the European Medicines Agency (EMA) as the designated reference regulator. The MHRA, as the UK's primary regulator for medicines and medical devices, ensures that all authorized products are both effective and acceptably safe, with decisions grounded in robust, fact-based judgments that confirm the benefits outweigh any inherent risks. This pathway facilitates the efficient introduction of new, critically needed treatments like plozasiran familial chylomicronaemia syndrome into the UK market.

For legal and compliance professionals, this authorization underscores the evolving landscape of market access and regulatory requirements for pharmaceutical products. Compliance officers should particularly note the specific conditions of use for plozasiran, the regulatory pathway utilized (IRP Route B), and the ongoing post-marketing surveillance via the Yellow Card scheme. Further detailed information regarding this FCS treatment UK will be made available in the Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL), which are slated for publication on the MHRA Products website, providing essential resources for healthcare providers and patients alike.

Lawyers advising pharmaceutical companies or healthcare providers should note this new authorization for market access, regulatory compliance, and patient information requirements. Compliance officers should be aware of the specific conditions of use, the regulatory pathway (IRP Route B), and the ongoing safety monitoring via the Yellow Card scheme for this new treatment option.

Source: Original reporting via MHRA announcement